European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability